SAN FRANCISCO, January 27, 2016 /PRNewswire/ --
The global transfection reagent & equipment market is expected to reach USD 1,086.02 million by 2022, according to a new report by Grand View Research, Inc. This anticipated growth in demand can be attributed to growing need for protein production, biopharmaceutical development, and vaccine research and development; all of which rely heavily on cytological R&D and transfection.
(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )
Browse full research report with TOC on "Transfection Reagent & Equipment Market Analysis By Method (DEAE-dextran, Calcium Phosphate, Activated Dendrimers, Magnetic Beads, Liposomes, Microinjection, Electroporation, Particle Bombardment, Laserfection, Adenoviral Vectors), By Application (Biomedical Research, Gene Expression, Studies, Cancer Research, Transgenic Models, Protein Production, Therapeutic Delivery) And Segment Forecasts To 2022" at: http://www.grandviewresearch.com/industry-analysis/transfection-reagents-and-equipment-market
Larger market entities are also involved in efforts to expand their market presence in the Asia Pacific region and tap the high potential for growth available. Expected growth of genomic and proteomic research is also a strong factor which will positively impact the growth in demand for transfection.
Further key findings from the report suggest:
- Out of both the broad segments of products available, transfection equipment accounted for a larger share of the market in 2014 and owing to their inherently more expensive nature than reagents are expected to maintain this dominant position over the forecast period.
- The market space for transfection has an abundant number of methods to achieve the aforementioned. However, these vary significantly in usage rates and implementation complexities. Electroporation and liposomal transfection combine to account for over 30% of the market owing to high associated advantages.
- Growing applications of transfection techniques poise the segments in a strong position and estimated valuation clocks usage of transfection in gene expression at over USD 130 million and for protein production at over USD 110 million for the year 2014.
- North America was observed to be responsible for the largest share of revenue in 2014 which amounted to a little over USD 240 million. The United States houses the headquarters of operations for a number of market leaders and a number of established research and development. This provides a strong platform for development, manufacture & distribution various vaccines, and biopharmaceuticals which fuels market growth.
- However, it is Asia Pacific region which is anticipated to witness significant growth over the forecast period in various segments owing to considerable growth of cytological research, development of biosimilar drugs and high potential of growth in these relatively untapped regional segments.
- Asia Pacific is expected to grow at a significant rate over the forecast period in terms of increasing production and development of vaccines, drugs, and new biologics. Supportive government initiatives pertaining to increasing investments by manufacturers and governments in biopharmaceutical manufacturing and high untapped market opportunities are the important factors accounting for the expected growth of market in this region over the forecast period.
- Promega, Roche and Thermo Fisher owned Life Technologies accounted for the largest of revenue in 2014 and are involved in new product development for expansion of their portfolios over the forecast period. Acquisition of smaller players is also expected over the forecast period by larger companies
- Key market players in the Transfection Reagent & Equipment Market include BTX (Harvards Apparatus Inc.), SignaGen Laboratories, OriGene Technologies, EMD Millipore, VWR International LLC, Bio-Rad Laboratories Inc., Mirus Bio LLC, F. Hoffman-La Roche AG, Lonza AG, Life Technologies (Thermo Fisher), and Promega Corporation.
Grand View Research has segmented Transfection Reagent & Equipment Market on the basis of product, method, application, and region:
- Global Transfection reagents & equipment Product Outlook (Revenue, USD Million, 2012 - 2022)
- Global Transfection reagents & equipment Method Outlook (Revenue, USD Million, 2012 - 2022)
- Electroporation
- Liposomes
- Particle Bombardment
- Microinjection
- Adenoviral vectors
- Direct microinjection
- Calcium phosphate
- DEAE-dextran
- Magnetic beads
- Activated Dendrimers
- Laserfection
- Global Transfection reagents & equipment Application Outlook (Revenue, USD Million, 2012 - 2022)
- Gene expression studies
- Protein production
- Transgenic delivery
- Cancer research
- Biomedical research
- Transfection reagents & equipment Regional Outlook (Revenue, USD Million, 2012 - 2022)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Browse related reports by Grand View Research:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Read Our Blogs - mediafound.org, ni2014.org
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:sales@grandviewresearch.com
Web: http://www.grandviewresearch.com
Share this article